Business News

Ipsen to Acquire Oncology Assets from Merrimack

CAMBRIDGE, Mass., Jan. 8, 2017 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) (“Merrimack” or the “Company”) today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen (Euronext: IPN; ADR: IPSEY) for a transaction valued at up to $1.025 billion, plus up to $33 million in …

Read More »

CSL and Momenta Announce Collaboration and License Agreement to Develop Fc Multimer Programs

CAMBRIDGE, MA — Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic …

Read More »

Jounce Therapeutics Files for $75M IPO

CAMBRIDGE, Mass., January 3, 2017 –Jounce Therapeutics, a clinical-stage immuno-oncology company, has filed an initial public offering  through which it hopes to raise $75 million in 2017. The Cambridge, MA-based company was founded in 2012 and employs a two-pronged approach to therapy development: using a translational science platform that targets …

Read More »

RaNA Therapeutics Acquires Shire’s Messenger RNA Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)–RaNA Therapeutics, a leader in the discovery and development of a new class of medicines that target RNA, today announced the acquisition of the MRT platform, an mRNA therapy platform, developed by subsidiaries of Shire plc. In addition, Shire’s former MRT employees, the group focused on the development …

Read More »

Incyte and Merus Partner to Discover and Develop Bispecific Antibodies

WILMINGTON, Del. & UTRECHT, Netherlands–(BUSINESS WIRE)–Dec. 21, 2016– Incyte Corporation (NASDAQ:INCY) and Merus N.V. (NASDAQ:MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte …

Read More »

Allergan to Acquire Acelity L.P. Inc.’s LifeCell Corporation for $2.9 Billion

DUBLIN, Dec. 20, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, and Acelity today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments. The acquisition …

Read More »

Juno Therapeutics Defeats Kite Pharma’s Challenge to CAR T-Cell Patent

SEATTLE–(BUSINESS WIRE)–Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced that it has defeated an attempt to invalidate a patent exclusively licensed by Juno that covers, among other things, a chimeric antigen receptor (CAR) T cell used for the treatment …

Read More »

Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-Focused Biotech

CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands–(BUSINESS WIRE)–Harbour BioMed, a recently established Shanghai-based company, today announced it has acquired Harbour Antibodies BV for cash and an equity interest in Harbour BioMed to create a new, global oncology-focused biotechnology company. The new company plans to leverage Harbour Antibodies’ patented transgenic …

Read More »

PGDx Launches CancerSELECT 125 Test for Pan-Cancer Tumor Profiling

BALTIMORE, Dec. 19, 2016 /PRNewswire/ — Personal Genome Diagnostics Inc. (PGDx), a leading provider of advanced cancer genome testing products and services, today announced the launch of its CancerSELECT™ 125 test for pan-cancer tumor profiling. CancerSELECT 125 identifies clinically actionable and functionally important sequence mutations and structural alterations across multiple …

Read More »

Celgene and Evotec Partner for Development of Drugs for Neurodegenerative Diseases

HAMBURG, Germany–(BUSINESS WIRE)–* Exclusive broad R&D collaboration based on Evotec’s unique induced pluripotent stem cell (“iPSC”) platform which enables systematic drug screening in patient-derived disease models Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation have entered into a strategic drug discovery and …

Read More »